GSK inks licensing deal for liver disease drug

In the deal worth up to $690 million for GSK, Italy-headquartered Alfasigma will acquire worldwide rights to linerixibat pending FDA approval.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Masimo convinces judge that Apple took secrets—but it’s not enough

19 March 2026 Although the court agreed that the tech giant misappropriated some of Masimo’s information related to pulse oximetry technology, Apple is not barred from using it, says a California judge.

Americas

J&J unit targets former employee over alleged mass data theft

17 March 2026 Janssen seeks injunctive relief after a forensic review uncovers mass downloads of trade secrets spanning oncology, neuroscience and immunology portfolios.

Americas

Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs

10 March 2026 The telehealth platform’s shares jumped more than 40% after the news that it will sell Ozempic and Wegovy—and no longer faces a lawsuit from the Danish pharma giant.

More features

IndiaMart v CDSCO: A test of intermediary liability

UPC appeals court upholds Abbott injunction in glucose monitoring patent dispute

CRISPR priority feud ends at USPTO as board reaches decision

Novartis bets $2bn on biologics as Xolair patents fade

WIPR debuts Global In-House Elite 2026

mRNA litigation: Who’s winning, who’s filing, and what’s next

Dechert boosts litigation bench with partner duo

UK court deals blow to Spanish pharma’s SPC bid for contraceptive

GSK inks licensing deal for liver disease drug

More on this story

Editor's picks

Editor's picks

More features